1 Therapies|Clear filters
Reg. name: Velcade®
Class: Proteasome Inhibitor
Bortezomib is a proteasome inhibitor, that specifically inhibits the chymotrypsin-like activity of the 26S proteasome in mammalian cells, which degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the turnover of specific proteins, thereby maintaining homeostasis within cells. The Summary of Product Characteristics for VELCADE® states that, inhibition of the 26S proteasome prevents targeted proteolysis and affects multiple signaling cascades within the cell, ultimately resulting in cancer cell death.
VELCADE® (bortezomib) for Injection is indicated for the treatment of patients with multiplemyeloma.
|Disease:||Patients eligible for transplant, Patients non-eligible for transplant, Elderly patients, Relapsed/refractory patients, General MM,|